- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01446731
Dendritic Cell Vaccination and Docetaxel for Patients With Prostate Cancer
Dendritic Cell Vaccination in Combination With Docetaxel for Patients With Cancer Prostate - a Randomized Phase II Study
This is a randomized phase II trial including 40 patients with castration resistant metastatic cancer prostate (CRMPC).
Patients will be randomized between treatment with a dendritic cell vaccine plus docetaxel and docetaxel alone.
The primary objective is to evaluate the vaccine specific immune response and patients will be evlauated with blood tests and DTH reactions during the treatment course.
Secondary objectives are to evaluate clinical response by objective response (RECIST-criteria, 18F-NaF-PET/CT scan), PSA response, pain response and finally we determine time to progression and overall survival.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Treatment in details:
Dendritic cell (DC) vaccination The DC vaccine consists of adherent monocytes collected by leukapheresis. Monocytes are stimulated with GM-CSF and IL-4, and IL-1β, TNFα, IL-6 and PGE2 are used for further maturation.
DCs are transfected with PSA, PAP, survivin and hTERT mRNA. DC vaccines will only be given to patients in ARM A
Docetaxel:
Docetaxel will be given as an i.v. infusion every third week, 75 mg/m2 according to standard treatment. Patients will be pretreated with prednisolon before infusion with Docetaxel. Continuous treatment with prednisolon will not be administered.
Treatment schedule:
The DC vaccination will be administered once a week in two out of three weeks for the first 12 weeks. After 12 weeks the DC vaccination will be given once every three weeks as long as Docetaxel is given. If the disease does not progress but the patient stop treatment with Docetaxel (because of side effects) the vaccine treatment can continue until disease progression.
Evaluation in details:
Immunological evaluation:
Blood tests:
100 ml blood will be drawn from the patient together with the first (baseline), the third and the fourth infusion of Docetaxel, and every third month thereafter.
DTH:
DTH with 3 i.d. injections consisting of media (neg. test), naked DCs and mRNA transfected DCs will be performed at baseline (together with 1st vaccine), together with the 5th vaccine and after three months of treatment (8th vaccine). 48 hours after the DTH at 5th vaccine a biopsy will be taken from the DTH area.
Clinical evaluation:
PSA:
Patients will be evaluated with PSA measurements during the treatment. All patients will receive at least 4 treatments with Docetaxel even if PSA is rising.
18F-NaF ("bone") PET/CT scan: All patients will have a bone-PET/CT scan at baseline. For patients with measurable lesions a PET/CT scan will be performed every three months.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Herlev, Denmark, 2730
- Department of Oncology, Herlev Hospital
-
-
Herlev
-
Copenhagen, Herlev, Denmark, 2730
- Center for Cancer Immune Therapy, Dept. of Haematology/Oncology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Histological verified CRMPC in progression, defined by
- RECIST-criteria and/or
- PSA increase to more than baseline in two consecutive measurements
- Treatment with Docetaxel is indicated
- Age > 18 years old
- ECOG performance status ≤2
- Life expectancy > 3 months
- Normal organ function
Exclusion Criteria:
- Other malignant tumors
- Severe heard or lung disorders
- Infection with HIV, hepatitis, tuberculosis.
- Severe allergy or previous anaphylactic reactions
- Active autoimmune disease
- Treatment with immunosuppressive drugs (including prednisolon, methotrexat)7. Co-treatment with other experimental treatments, other antineoplastic treatment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm A
DC vaccine (mRNA transfected dendritic cell) + Docetaxel
|
Autologues monocytes are matured into dendritic cells which are then transfected with mRNA from PSA, PAP, survivin and hTERT. 5x 10e6 DCs are given as intradermal injections in the groin Day 8 and Day 15 in a 3 week period repeated 4 times and thereafter Day 8 in a 3 week period until progression (no maximum duration).
Docetaxel 75 mg/m2 is given as an intravenous injection Day 1 every three weeks in a maximum of 12 cycles (1 cycle = 3 weeks).
Other Names:
|
Active Comparator: Arm B
Docetaxel alone
|
Docetaxel 75 mg/m2 is given as an intravenous injection Day 1 every three weeks in a maximum of 12 cycles (1 cycle = 3 weeks).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Immunological response
Time Frame: 2 years
|
The induction of vaccine specific immune responses will be assessed
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival
Time Frame: 4 years
|
4 years
|
|
Toxicity
Time Frame: 2 years
|
2 years
|
|
Time to progression
Time Frame: 4 years
|
4 years
|
|
Clinical response
Time Frame: 2 years
|
Clinical response will be assessed using PSA measurements, pain response and PET/CT scans (according to RECIST)
|
2 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Per Kongsted, MD, CCIT / Department of Oncology, Herlev Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- UR1121
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostatic Neoplasms
-
Australian and New Zealand Urogenital and Prostate...Peter MacCallum Cancer Centre, AustraliaRecruitingCastration Resistant Prostatic CancerAustralia
-
Technische Universität DresdenRecruitingOligometastatic Disease | Prostatic Cancer, Castration-ResistantGermany
-
British Columbia Cancer AgencySanofi; Ozmosis Research Inc.UnknownMetastatic Castration-Resistant Prostatic CancerCanada, Australia
-
Yinghao SunNot yet recruitingCastration-Resistant Prostatic Cancer
-
Institut Claudius RegaudWithdrawnProstatic Cancer, Castration-ResistantFrance
-
Janssen Research & Development, LLCCompletedCastration-Resistant Prostatic NeoplasmsCanada, Belgium, United States, Spain, Netherlands, Italy, Russian Federation
-
Universität des SaarlandesRecruitingProstate Cancer Metastatic | Advanced Prostate Carcinoma | Castration Resistant Prostatic CancerGermany
-
University Hospital, GrenobleTerminatedCastration-resistant Prostate CancerFrance
-
Rio de Janeiro State UniversityCompletedProstatic Cancer | Prostatic NeoplasmBrazil
-
Michael Graham PhD, MDUniversity of Iowa; Holden Comprehensive Cancer CenterActive, not recruitingProstate Cancer | Prostatic Neoplasms, Castration-Resistant | Prostatic Neoplasm | Prostatic Cancer Recurrent | Prostatic Cancer MetastaticUnited States
Clinical Trials on mRNA transfected dendritic cell
-
Massachusetts General HospitalNational Institute of Allergy and Infectious Diseases (NIAID)CompletedHIV Infections | HIV-1 InfectionUnited States
-
National Center for Research Resources (NCRR)Duke UniversityUnknown
-
Steinar AamdalTerminatedMetastatic Malignant MelanomaNorway
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)TerminatedRecurrent Renal Cell Carcinoma | Stage I Renal Cell Cancer | Stage II Renal Cell CancerUnited States
-
Oslo University HospitalCompletedGlioblastoma | Brain Tumor
-
US Department of Veterans AffairsCompleted
-
Scott PruittCompletedMetastatic Melanoma | Absence of CNS MetastasesUnited States
-
Radboud University Medical CenterRotterdam Eye HospitalTerminated
-
University of PittsburghTerminatedSquamous Cell Carcinoma of the Head and Neck | Primary Advanced Carcinoma of the Oral Cavity or OropharynxUnited States
-
Hospital Clinic of BarcelonaCompleted